Your browser doesn't support javascript.
DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
Krejner-Bienias, Alicja; Grzela, Katarzyna; Grzela, Tomasz.
  • Krejner-Bienias A; Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.
  • Grzela K; Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.
  • Grzela T; Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland. tomasz.grzela@wum.edu.pl.
Arch Immunol Ther Exp (Warsz) ; 69(1): 1, 2021 Feb 02.
Article in English | MEDLINE | ID: covidwho-1059378
ABSTRACT
A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Dipeptidyl Peptidase 4 / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Arch Immunol Ther Exp (Warsz) Year: 2021 Document Type: Article Affiliation country: S00005-020-00602-5

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Dipeptidyl Peptidase 4 / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Arch Immunol Ther Exp (Warsz) Year: 2021 Document Type: Article Affiliation country: S00005-020-00602-5